MentionFox
Home › Executive changes › Beam Therapeutics Inc.
Leadership changes · BEAM · SEC Form 8-K, Item 5.02

Leadership changes at Beam Therapeutics Inc. (2026)

Before you join, sell to or invest in Beam Therapeutics Inc.

MentionFox check on Beam Therapeutics Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/beam-therapeutics

Check Beam Therapeutics Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Beam Therapeutics Inc.?

Who joined and who left Beam Therapeutics Inc. (BEAM)? 1 filing reported on 2026-02-05, each cited to the company's own filing.

As of November 14, 2026, Beam Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 5, 2026 (Form 8-K, February 5, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Farallon Capital Management, L.L.C. also filed stake reports on 19 other companies ↓

Sell to companies like Beam Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-02-05

Beam Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-05. Every row below is cited to the filing it comes from, and this page adds each new change as Beam Therapeutics Inc. files it.

Also on the record for Beam Therapeutics Inc.

DateRecordFigureOur pageSource
November 13, 2026Stake report, Schedule 13G/A, by ARK Investment Management LLC11.43% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by ARK Investment Management LLC9.95% of the class5%+ stakesSource
August 13, 2026Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C.9.99% of the class5%+ stakesSource
April 29, 2026Stake report, Schedule 13G, by Vanguard Capital Management5.02% of the class5%+ stakesSource
March 26, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 9, 2026Stake report, Schedule 13G, by STATE STREET CORPORATION5.2% of the class5%+ stakesSource
February 5, 2026Stake report, Schedule 13G/A, by Dapice Joshua J.9.99% of the class5%+ stakesSource
February 5, 2026Stake report, Schedule 13G/A, by FMR LLC12.6% of the class5%+ stakesSource
February 3, 2026Stake report, Schedule 13G/A, by ARK Investment Management LLC12.29% of the class5%+ stakesSource
November 5, 2025Stake report, Schedule 13G/A, by FMR LLC13.6% of the class5%+ stakesSource
August 7, 2025Stake report, Schedule 13G/A, by ARK Investment Management LLC10.35% of the class5%+ stakesSource
August 6, 2025Stake report, Schedule 13G/A, by FMR LLC15% of the class5%+ stakesSource

Selling to them or working with them? See who runs Beam Therapeutics Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Beam Therapeutics Inc. and the records around it.

Beam Therapeutics Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Beam Therapeutics Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Beam Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Beam Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-05Reportednot named in the filing8-K, 2026-02-05
Selling to Beam Therapeutics Inc.?

New leaders reset buying decisions — get the Full Report on Beam Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Beam Therapeutics Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Beam Therapeutics Inc., with the record behind each one.

Find candidates like senior executive at Beam Therapeutics Inc.

Every change, in the filing's words

Filed 2026-02-05 · 8-K

Reported

On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the "Company") with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026.

Also stated in this filing

  • Dr. Ho's decision to resign did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Tools for this story

Each opens in a new tab, filled in for Beam Therapeutics Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/beam-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Beam Therapeutics Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/beam-therapeutics